Clinical Trials Logo
  1. Home
  2. Healthy
  3. NCT00857571
  4. Details
NCT00857571 Clinical Trial

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Healthy Clinical Trial

Official title:
An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00857571
Other study ID # B0461003
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date April 2009
Est. completion date May 2009

Study information
Verified date December 2018
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets

Recruitment information / eligibility
Status Terminated
Enrollment 12
Est. completion date May 2009
Est. primary completion date May 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 55 Years
Eligibility Inclusion Criteria:

- Healthy male and female volunteers.

- Female volunteers have to be of non-childbearing potential

Exclusion Criteria:

- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

- Any condition possibly affecting drug absorption (eg, gastrectomy).

- A positive urine drug screen.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• 150 mg Suspension
Single oral dose of 150 mg of PF-02413873 suspension
• 30 mg Suspension
Single oral dose of 30 mg of PF-02413873 suspension
• 400 mg Suspension
Single oral dose of 400 mg of PF-02413873 suspension
• 5 mg Suspension
Single oral dose of 5 mg of PF-02413873 suspension
• 750 mg Suspension
Single oral dose of 750 mg of PF-02413873 suspension
• 150 mg Tablet
Single oral dose of 150 mg of PF-02413873 tablets
• 30 mg Tablet
Single oral dose of 30 mg of PF-02413873 tablets
• 400 mg Tablet
Single oral dose of 400 mg of PF-02413873 tablets
• 5 mg Tablet
Single oral dose of 5 mg of PF-02413873 tablets
• 750 mg Tablet
Single oral dose of 750 mg of PF-02413873 tablets

Locations
Country Name City State
Singapore Pfizer Investigational Site Singapore

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Singapore, 

Outcome
Type Measure Description Time frame Safety issue
Primary Pharmacokinetics: Cmax, AUCinf June - July 2009
Secondary Tmax, Tlag, AUClast, AUCt, t½, Frel. June-July 2009
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1

External Links